IRON | Disc Medicine Opco Inc | [NASD]
Index- P/E- EPS (ttm)-4.82 Insider Own0.60% Shs Outstand18.95M Perf Week-3.76%
Market Cap634.66M Forward P/E- EPS next Y-4.14 Insider Trans- Shs Float16.37M Perf Month0.90%
Income-54.40M PEG- EPS next Q-0.88 Inst Own85.10% Short Float / Ratio1.86% / 2.76 Perf Quarter33.37%
Sales- P/S- EPS this Y84.90% Inst Trans5.25% Short Interest0.30M Perf Half Y92.49%
Book/sh12.28 P/B2.65 EPS next Y-5.60% ROA-32.80% Target Price40.75 Perf Year159.20%
Cash/sh12.12 P/C2.68 EPS next 5Y- ROE-35.00% 52W Range11.80 - 37.48 Perf YTD63.55%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-13.21% Beta-
Dividend %- Quick Ratio24.30 Sales past 5Y- Gross Margin- 52W Low175.68% ATR2.34
Employees46 Current Ratio24.30 Sales Q/Q- Oper. Margin- RSI (14)56.22 Volatility8.10% 7.49%
OptionableYes Debt/Eq0.00 EPS Q/Q65.90% Profit Margin- Rel Volume0.48 Prev Close32.05
ShortableYes LT Debt/Eq0.00 EarningsMar 31 BMO Payout- Avg Volume110.53K Price32.53
Recom1.60 SMA20-0.51% SMA5018.41% SMA20057.80% Volume53,510 Change1.50%
Date Action Analyst Rating Change Price Target Change
May-17-23Initiated Raymond James Outperform $50
Apr-28-23Initiated Cantor Fitzgerald Overweight $45
Apr-21-23Initiated Stifel Buy $37
Apr-20-23Initiated Morgan Stanley Overweight $37
Mar-23-23Initiated BMO Capital Markets Outperform $40
Feb-28-23Initiated SVB Securities Outperform $36
May-15-23 07:00AM
May-11-23 10:15AM
May-10-23 10:23AM
May-05-23 08:50AM
May-04-23 12:00PM
05:00AM Loading…
Apr-28-23 05:00AM
Apr-27-23 08:05AM
Apr-21-23 08:30AM
Apr-19-23 08:50AM
Apr-13-23 11:00AM
Mar-31-23 07:00AM
Mar-30-23 07:05AM
Mar-21-23 07:00AM
Feb-16-23 08:00AM
Feb-14-23 06:30AM
04:00PM Loading…
Feb-08-23 04:00PM
Jan-20-23 07:00AM
Disc Medicine Opco Inc, together with its subsidiaries, operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria. In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AI DMI LLC10% OwnerFeb 15Buy23.00434,78310,000,0093,141,759Feb 17 04:42 PM
Ashiya MonaDirectorFeb 15Buy23.00108,6962,500,0081,196,825Feb 17 04:48 PM
ORBIMED ADVISORS LLCDirectorFeb 15Buy23.00108,6962,500,0081,196,825Feb 17 04:43 PM